BNP Paribas Call 480 LONN 20.12.2.../ DE000PN7C6M8 /
9/3/2024 9:51:59 AM | Chg.-0.030 | Bid1:22:46 PM | Ask1:22:46 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.850EUR | -3.41% | 0.820 Bid Size: 53,000 |
0.840 Ask Size: 53,000 |
LONZA N | 480.00 CHF | 12/20/2024 | Call |
GlobeNewswire
8/8
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/6
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6/14
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
5/30
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
5/15
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
4/4
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
4/4
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire
2/27
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
1/4
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire
12/19/2023
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire
12/9/2023
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire
12/7/2023
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire
11/6/2023
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
10/16/2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire
10/2/2023
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
9/20/2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023